AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25738793 — intervention group
Group type: EXPERIMENTAL
Intervention: RCL (rescuers changed by a team leader's decision)
Number of subjects: 96
Study 25738793 — intervention group
Group type: COMPARATOR
Intervention: RC2 (conventional rescuer rotation method, rescuers changed in 2-min intervals)
Number of subjects: 96
Study 25738793 — intervention group
Group type: EXPERIMENTAL
Intervention: RCL
Number of subjects: 96
Study 25738793 — intervention group
Group type: COMPARATOR
Intervention: RC2
Number of subjects: 96
Study 25335248 — intervention group
Group type: EXPERIMENTAL
Intervention: Scraping therapy (44 cases)
Number of subjects: 85
Study 25335248 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture therapy (41 cases)
Number of subjects: 85
Study 25335248 — intervention group
Group type: EXPERIMENTAL
Intervention: Both scraping and acupuncture therapies
Number of subjects: 85
Study 25335248 — intervention group
Group type: EXPERIMENTAL
Intervention: Scraping therapy
Number of subjects: 85
Study 23660718 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic fundus‐first dissection
Number of subjects: 0
Study 23660718 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy using electrocautery
Number of subjects: 0
Study 20631341 — intervention group
Group type: EXPERIMENTAL
Intervention: 3B(90)E(500)P (30 kU bleomycin on days 1, 8, and 15; 100 mg/m(2) etoposide on days 1‐5; 20 mg/m(2) cisplatin on days 1‐5; n = 83)
Number of subjects: 166
Study 20631341 — intervention group
Group type: COMPARATOR
Intervention: 4B(30)E(360)P (30 kU bleomycin on day 1; 120 mg/m(2) etoposide on days 1‐3; 100 mg/m(2) cisplatin on day 1; n = 83)
Number of subjects: 166
Study 20631341 — intervention group
Group type: EXPERIMENTAL
Intervention: 3B(90)E(500)P
Number of subjects: 166
Study 20631341 — intervention group
Group type: COMPARATOR
Intervention: 4B(30)E(360)P
Number of subjects: 166
Study 19378539 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine (S50-R50)
Number of subjects: 75
Study 19378539 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine (S75-R25)
Number of subjects: 75
Study 19378539 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine (S75-R25)
Number of subjects: 75
Study 16804655 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (P/T) at 4 g/0.5 g
Number of subjects: 221
Study 16804655 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin (I/C) at 1 g/1 g
Number of subjects: 221
Study 16804655 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (P/T)
Number of subjects: 221
Study 16804655 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin (I/C)
Number of subjects: 221
Study 15014276 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafton DBM
Number of subjects: 120
Study 15014276 — intervention group
Group type: COMPARATOR
Intervention: Iliac crest autograft
Number of subjects: 120
Study 15014276 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Grafton DBM and Iliac crest autograft
Number of subjects: 120
Study 11544831 — intervention group
Group type: EXPERIMENTAL
Intervention: Endolymphic infusion of immunomodulator
Number of subjects: 85
Study 11544831 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional infusion of considerable doses of cytostatic mixes
Number of subjects: 85
Study 9750678 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (C)
Number of subjects: 12
Study 9750678 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 12
Study 8144799 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin
Number of subjects: 246
Study 8144799 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 246
Study 3415886 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine with adrenaline 1 in 200,000 in the lateral position
Number of subjects: 64
Study 3415886 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% plain bupivacaine in the sitting position
Number of subjects: 64
Study 3415886 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotension (defined as a 25% or greater reduction in arterial pressure)
Number of subjects: 64
Study 31418585 — intervention group
Group type: EXPERIMENTAL
Intervention: Abaloparatide 80 µg daily
Number of subjects: 2463
Study 31418585 — intervention group
Group type: COMPARATOR
Intervention: Teriparatide 20 µg daily
Number of subjects: 2463
Study 31418585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2463
Study 28493932 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (3×105 U to 80×105 U)
Number of subjects: 51
Study 28493932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 26242335 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic lumbar posterior instrumentation
Number of subjects: 53
Study 26242335 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment with an exercise program
Number of subjects: 53
Study 23545150 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 18
Study 23545150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 21496991 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized motivational intervention (PMI)
Number of subjects: 218
Study 21496991 — intervention group
Group type: COMPARATOR
Intervention: Health-information (HI) control
Number of subjects: 218
Study 19559433 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on skills training for therapeutic endoscopic procedures
Number of subjects: 28
Study 19559433 — intervention group
Group type: COMPARATOR
Intervention: Knowledge-based teaching
Number of subjects: 28
Study 19559433 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hands-on skills training)
Number of subjects: 28
Study 16374763 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound after first-trimester uterine evacuation
Number of subjects: 809
Study 16374763 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ultrasound)
Number of subjects: 809
Study 12757679 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ligation (Inguinal approach/Ivanissevich's procedure) - Group I (n: 115)
Number of subjects: 213
Study 12757679 — intervention group
Group type: COMPARATOR
Intervention: High ligation (Retroperitoneal approach/modified Palomo's procedure) - Group II (n: 98)
Number of subjects: 213
Study 10967180 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation of digital nerves at frequencies of 2 Hz, 3 Hz, 5 Hz, 7 Hz, and 9 Hz with 500 stimuli given at each frequency.
Number of subjects: 20
Study 10967180 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflex responses recorded from the triceps brachii muscle in 8 subjects.
Number of subjects: 20
Study 9118190 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine/xylitol chewing gum
Number of subjects: 53
Study 9118190 — intervention group
Group type: COMPARATOR
Intervention: Xylitol placebo chewing gum
Number of subjects: 53
Study 8416238 — intervention group
Group type: EXPERIMENTAL
Intervention: High-current stimulation
Number of subjects: 11
Study 8416238 — intervention group
Group type: COMPARATOR
Intervention: Low-current stimulation
Number of subjects: 11
Study 2944534 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyloestradiol 50 micrograms/cyproterone acetate 50 mg
Number of subjects: 24
Study 2944534 — intervention group
Group type: COMPARATOR
Intervention: Ethinyloestradiol 50 micrograms/norgestrel 500 micrograms (Eugynon 50)
Number of subjects: 24
Study 30770539 — intervention group
Group type: EXPERIMENTAL
Intervention: Slightly sweet lipid-based nutrient supplement (LNS)
Number of subjects: 985
Study 30770539 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-LNS) received iron and folic acid or multiple micronutrients
Number of subjects: 985
Study 30770539 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-LNS)
Number of subjects: 985
Study 28180236 — intervention group
Group type: EXPERIMENTAL
Intervention: Community In‐reach Rehabilitation and Care Transition (CIRACT) service
Number of subjects: 250
Study 28180236 — intervention group
Group type: COMPARATOR
Intervention: Traditional hospital‐based rehabilitation (THB‐Rehab) service
Number of subjects: 250
Study 28180236 — intervention group
Group type: EXPERIMENTAL
Intervention: CIRACT service
Number of subjects: 250
Study 28180236 — intervention group
Group type: COMPARATOR
Intervention: THB‐Rehab service
Number of subjects: 250
Study 26097440 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.4 g · kg(‐1) body weight)
Number of subjects: 13
Study 24332698 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic cardioversion (PCV)
Number of subjects: 2972
Study 24332698 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical cardioversion (ECV)
Number of subjects: 2972
Study 22588508 — intervention group
Group type: EXPERIMENTAL
Intervention: Video feedback intervention (n = 25)
Number of subjects: 74
Study 22588508 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal feedback intervention (n = 26)
Number of subjects: 74
Study 22588508 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n = 23)
Number of subjects: 74
Study 19139776 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (n=27) received 15 ml (102.5mg) of 0.75% solution
Number of subjects: 81
Study 19139776 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (n=27) received 10 ml (75 mg) of 0.75% solution
Number of subjects: 81
Study 19139776 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III (n=27) received 10 ml (50mg) 0.5% ropivacaine
Number of subjects: 81
Study 18232268 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-fortified salt (DFS)
Number of subjects: 286
Study 18232268 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodised salt plus weekly 70 mg iron supplement (IS + iron)
Number of subjects: 286
Study 18232268 — intervention group
Group type: COMPARATOR
Intervention: Iodised salt (IS) plus weekly placebo (control group)
Number of subjects: 286
Study 18232268 — intervention group
Group type: COMPARATOR
Intervention: Iodised salt (IS) (control group)
Number of subjects: 286
Study 18232268 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups of women and children
Number of subjects: 286
Study 15111940 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical methods, especially with the use of biological feedback
Number of subjects: 173
Study 15111940 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological treatments
Number of subjects: 173
Study 15111940 — intervention group
Group type: COMPARATOR
Intervention: Combination of pharmacological and physical treatments
Number of subjects: 173
Study 11758290 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrater agreement between two readers
Number of subjects: 160
Study 11758290 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrater agreement between readers and authors
Number of subjects: 160
Study 11758290 — intervention group
Group type: EXPERIMENTAL
Intervention: Categories assigned by methodologists
Number of subjects: 160
Study 11758290 — intervention group
Group type: EXPERIMENTAL
Intervention: Categories assigned by authors
Number of subjects: 160
Study 9741655 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide (HBB) 10 mg
Number of subjects: 10
Study 9741655 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulphate 0.4 mg
Number of subjects: 10
Study 9741655 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 10
Study 8059044 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1 microgram/kg/h and bupivacaine 0.125% with boluses of 12.5 micrograms fentanyl and bupivacaine at 0.125%
Number of subjects: 20
Study 8059044 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (control group)
Number of subjects: 20
Study 3058102 — intervention group
Group type: EXPERIMENTAL
Intervention: Tono-Pen
Number of subjects: 115
Study 3058102 — intervention group
Group type: COMPARATOR
Intervention: MacKay-Marg tonometer
Number of subjects: 115
Study 30864532 — intervention group
Group type: EXPERIMENTAL
Intervention: Home treatment alternative to hospital care (experimental group)
Number of subjects: 707
Study 30864532 — intervention group
Group type: COMPARATOR
Intervention: Conventional service model without home treatment (control group)
Number of subjects: 707
Study 31486730 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon-PC team co-management
Number of subjects: 0
Study 31486730 — intervention group
Group type: COMPARATOR
Intervention: Surgeon-alone management
Number of subjects: 0
Study 28632865 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab combined with mFOLFOX6 or FOLFIRI chemotherapy
Number of subjects: 1137
Study 28632865 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab combined with mFOLFOX6 or FOLFIRI chemotherapy
Number of subjects: 1137
Study 28632865 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 1137
Study 28632865 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 1137
Study 26156277 — intervention group
Group type: EXPERIMENTAL
Intervention: CCLAD
Number of subjects: 120
Study 26156277 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% benzocaine
Number of subjects: 120
Study 26156277 — intervention group
Group type: COMPARATOR
Intervention: Cartridge syringe
Number of subjects: 120
Study 26156277 — intervention group
Group type: COMPARATOR
Intervention: Pressure with cotton applicator
Number of subjects: 120
Study 26156277 — intervention group
Group type: COMPARATOR
Intervention: No topical application
Number of subjects: 120
Study 23842741 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinoplasty with defatting tip and supratip skin
Number of subjects: 55
Study 23842741 — intervention group
Group type: COMPARATOR
Intervention: Rhinoplasty without defatting tip and supratip skin (control group)
Number of subjects: 55
Study 21132546 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine supplementation (CAF)
Number of subjects: 6
Study 21132546 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 6
Study 21132546 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 6
Study 21132546 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine supplementation (CAF) and Exercise
Number of subjects: 6
Study 19110505 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 160
Study 19110505 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 160
Study 17031654 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous ureteric catheter insertion
Number of subjects: 24
Study 17031654 — intervention group
Group type: COMPARATOR
Intervention: Sequential ureteric catheter insertion
Number of subjects: 24
Study 15173489 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent reports of ADHD symptoms
Number of subjects: 1445
Study 15173489 — intervention group
Group type: COMPARATOR
Intervention: Teacher reports of ADHD symptoms
Number of subjects: 1445
Study 15569286 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Intervention Programme (EIP)
Number of subjects: 23
Study 15569286 — intervention group
Group type: COMPARATOR
Intervention: Control (routine medical nursing care)
Number of subjects: 23
Study 10077720 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresonance therapy (10 sessions)
Number of subjects: 14
Study 10077720 — intervention group
Group type: COMPARATOR
Intervention: Speech therapy (control group)
Number of subjects: 14
Study 10077720 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech therapy (after bioresonance therapy)
Number of subjects: 14
Study 10077720 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresonance therapy (after speech therapy)
Number of subjects: 14
Study 7740939 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional medial bone‐patellar tendon graft
Number of subjects: 40
Study 7740939 — intervention group
Group type: COMPARATOR
Intervention: Half‐thickness patellar tendon graft augmented with the Kennedy Ligament Augmentation Device (LAD)
Number of subjects: 40
Study 2184133 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram 100 mg
Number of subjects: 15
Study 2184133 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram 400 mg
Number of subjects: 15
Study 2184133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7288210 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (high DNAP levels)
Number of subjects: 20
Study 7288210 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (low DNAP levels)
Number of subjects: 20
Study 7288210 — intervention group
Group type: COMPARATOR
Intervention: Group 1 and Group 2
Number of subjects: 20
Study 7288210 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral replication
Number of subjects: 20
Study 30394337 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led complex package of care for gout
Number of subjects: 30
Study 30306603 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-FODMAP diet
Number of subjects: 20
Study 30306603 — intervention group
Group type: COMPARATOR
Intervention: Typical-Australian diet
Number of subjects: 20
Study 26572280 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (1.0 mA anodal stimulation over the left DLPFC with cathodal stimulation over the right supra-orbital area)
Number of subjects: 25
Study 26572280 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 25
Study 24874344 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective interval appendectomy (IA), median interval 76 days, range 29-230 days
Number of subjects: 69
Study 24874344 — intervention group
Group type: COMPARATOR
Intervention: Emergency appendectomy
Number of subjects: 69
Study 24874344 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 69
Study 21703848 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative treatment according to the localised-disease protocol
Number of subjects: 103
Study 21703848 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative treatment according to the metastatic-disease protocol
Number of subjects: 103
Study 21703848 — intervention group
Group type: COMPARATOR
Intervention: True localised disease
Number of subjects: 103
Study 21703848 — intervention group
Group type: COMPARATOR
Intervention: Metastatic disease
Number of subjects: 103
Study 19829096 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 international units daily for 12 weeks)
Number of subjects: 19
Study 19829096 — intervention group
Group type: COMPARATOR
Intervention: Control group not mentioned
Number of subjects: 19
Study 19425483 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental dyslexia (W, S, M)
Number of subjects: 176
Study 19425483 — intervention group
Group type: COMPARATOR
Intervention: Control group (children without ophthalmological pathological state)
Number of subjects: 176
Study 16249540 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruboxistaurin 32 mg/day for 1 year
Number of subjects: 123
Study 16249540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 11852155 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth shape presented in isolation
Number of subjects: 0
Study 11852155 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth shape embedded in original photos
Number of subjects: 0
Study 11852155 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth shape in exchanged facial context
Number of subjects: 0
Study 11852155 — intervention group
Group type: EXPERIMENTAL
Intervention: Conflicting mouth shape and facial context
Number of subjects: 0
Study 11852155 — intervention group
Group type: EXPERIMENTAL
Intervention: Attended stimuli in correct facial context
Number of subjects: 0
Study 11852155 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated mouth stimuli
Number of subjects: 0
Study 10102956 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg curcumin
Number of subjects: 12
Study 10102956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8703664 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg daily for 15 days
Number of subjects: 13
Study 29243058 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron IV (group O)
Number of subjects: 108
Study 29243058 — intervention group
Group type: COMPARATOR
Intervention: 4 ml saline (group S)
Number of subjects: 108
Study 28778993 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein, carbohydrate, and fat mixture (meal replacement)
Number of subjects: 8
Study 28778993 — intervention group
Group type: COMPARATOR
Intervention: Amino acid (AA) beverage
Number of subjects: 8
Study 25746712 — intervention group
Group type: EXPERIMENTAL
Intervention: ON-Q pain relief system
Number of subjects: 0
Study 23280270 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-and-About program
Number of subjects: 300
Study 23280270 — intervention group
Group type: COMPARATOR
Intervention: Written guidelines only
Number of subjects: 300
Study 21237167 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel follow-up system (letters to primary care provider, 2 letters to patient, telephone call)
Number of subjects: 830
Study 21237167 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (no follow-up system)
Number of subjects: 830
Study 21237167 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel follow-up system
Number of subjects: 830
Study 19488587 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage continuous curvilinear capsulorhexis (1-CCC)
Number of subjects: 24
Study 19488587 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage continuous curvilinear capsulorhexis (2-CCC)
Number of subjects: 24
Study 16500499 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelium‐dependent flow‐mediated dilation (FMD)
Number of subjects: 30
Study 16500499 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonendothelium‐dependent dilation
Number of subjects: 30
Study 16500499 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic strain
Number of subjects: 30
Study 16500499 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic distensibility
Number of subjects: 30
Study 15617613 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood vegetable intake
Number of subjects: 1227
Study 15617613 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood fruit intake
Number of subjects: 1227
Study 10791526 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatment schedule (10 daily injections of 2.2 mg/kg)
Number of subjects: 500